An observational study in Blood Disease, sponsored by QIAGEN Gaithersburg, Inc. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Hematologic Diseases with a site in United Kingdom — 7 open to participants now, 21 under way, 17 of them phase 3. Hematologic Diseases · United Kingdom.
Among the 70 studies in Hematologic Diseases with a site in United Kingdom, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 65th registered.
610 studies on the registry are indexed under Hematologic Diseases; 109 are open to participants now.
Browse Hematologic Diseases studies →7 of the 70 studies in Hematologic Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Takeda · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18+
Takeda · Sites in United Kingdom, United States, Australia and 15 more countries
Ages 18+
Loxo Oncology, Inc. · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 18+
Cogent Biosciences, Inc. · Sites in United Kingdom, United States, Australia and 11 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United Kingdom, United States, Canada and 7 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 73 Hematologic Diseases studies recruiting now, 46 (63%) set no upper age limit and 23 (32%) stop at 75 or younger; 28 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 22 · Phase 3 35 · Phase 4 2
First in 1994; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,142 is above the median of 250 across 127 observational studies indexed under Hematologic Diseases.
Median enrollment 120 across the 61 interventional studies, 162 across the 8 observational. Of the 45 that completed or were terminated, 31 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under QIAGEN Gaithersburg, Inc, one of the names counted as QIAGEN. Under that name alone:
QIAGEN Gaithersburg, Inc is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
QIAGEN has 1 study filed under Hematologic Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Hematologic Diseases with a site in United Kingdom that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Hematologic Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods
This multicenter study aims to evaluate the performance of QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel with another validated comparator method.
Patients suspected of bloodstream infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested
PPA
positive percentage agreement
Time frame: 6 moths
NPA
negative percentage agreement
Time frame: 6 moths
Plan to share: No — all samples are residual and anonymized
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Apr 2025, 16 months.
Of 64 observational studies under Hematologic Diseases, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 78. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.